can type 1 diabetics use glp-1 and GIP in Diabetes Therapy: A Time for Reappraisal? Is It Safe To Use

Considering the promising results of the SURPASS and SURMOUNT trials, what additional factors or challenges must researchers address before adopting tirzepatide for conditions beyond Type 2 diabetes, such as non-alcoholic fatty liver disease (NAFLD)

The binding of prorenin to PRR triggers the phosphorylation of mitogen-activated protein kinases/extracellular regulated kinases 1/2 (MAPK/ERK1/2), which is demonstrated to be an ANG II-independent mechanism involved in the development of diabetic nephropathy ( The ANGIV/AT4/IRAP cascade: ANG IV (derived from the metabolization of ANG II through aminopeptidases A and N) binds the AT4 receptor, which has been identified as the insulin-regulated aminopeptidase (IRAP), but the role of this pathway in the blood pressure and renal regulation is still uncertain ( These new axes have raised great interest because their targeting could provide novel therapeutic strategies for hypertension, cardiovascular and kidney diseases

GLP-1 signaling also antagonizes voltage-dependent K + (Kv) channels via cAMP/PKA-dependent pathway in beta cells, which prevents beta-cell repolarization by reducing Kv currents

Biogerontology 2024 , 25 , 83106

Thats when I found MDWatch